Manale El Kharbili, PhD, on a Novel Strategy to Eliminate MRD in HER2-Mutant NSCLC
AACR 2026
Manale El Kharbili, PhD, of the University of Colorado Anschutz Medical Campus, discusses preclinical work that showed HER2-mutant non–small cell lung cancer (NSCLC) cell lines retained demonstrated dynamic changes in cell surface protein expression in treatment-naive vs zongertinib-induced measurable residual disease (MRD) states. Tyrosine kinase inhibitor (TKI)-sensitive and TKI-resistant HER2-driven lines demonstrated high sensitivity to therapies targeting surface proteins, which correlated with their level of expression—representing a potential novel therapeutic strategy for eradicating MRD and preventing relapse in these patients (Abstract 3166).
Thi Van Trinh Tran, PhD, of the National Cancer Institute, describes histologic and prognostic findings from the largest cohort of lung cancer in people who have never smoked. Tumor-infiltrating lymphocyte data also reflected refined risk stratification (Abstract 1302).
Jonathan Riess, MD, of the University of California, Davis, describes preliminary data on the safety and clinical activity of zoldonrasib (also known as RMC-9805), an oral, RAS(ON) G12D–selective, tricomplex inhibitor, in previously treated patients with KRAS G12D–mutant non–small cell lung cancer (NSCLC) (Abstract CT021).
The ASCO Post Staff
Fabrice Barlesi, MD, PhD, of Gustave Roussy, discusses interim results from the phase II MATISSE trial, which looked at dual CD39 and PD-L1 inhibition in patients with resectable non–small cell lung cancer (NSCLC). The study investigated the combination of IPH5201, an investigational anti-CD39 monoclonal antibody, and the immune checkpoint inhibitor durvalumab plus platinum-based chemotherapy (Abstract CT231).
